Entera Bio Ltd Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Entera Bio Ltd has an operating margin of -5295.6%, meaning the company retains $-5296 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Entera Bio Ltd carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.63, Entera Bio Ltd holds $7.63 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Entera Bio Ltd generated -$6.8M in operating cash flow, capex of $3K consumed most of it, leaving -$6.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Entera Bio Ltd passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Entera Bio Ltd generates $0.71 in operating cash flow (-$6.8M OCF vs -$9.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Entera Bio Ltd (ENTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Entera Bio Ltd generated $181K in revenue in fiscal year 2024.
Entera Bio Ltd's EBITDA was -$9.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.0% from the prior year.
Entera Bio Ltd generated -$6.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 6.9% from the prior year.
Entera Bio Ltd reported -$9.5M in net income in fiscal year 2024. This represents a decrease of 7.3% from the prior year.
Entera Bio Ltd earned $0.25 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 19.4% from the prior year.
Entera Bio Ltd held $8.7M in cash against $0 in long-term debt as of fiscal year 2024.
Entera Bio Ltd had 39M shares outstanding in fiscal year 2024. This represents an increase of 9.5% from the prior year.
Entera Bio Ltd's gross margin was 5.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs.
Entera Bio Ltd's operating margin was -5295.6% in fiscal year 2024, reflecting core business profitability.
Entera Bio Ltd's net profit margin was -5271.3% in fiscal year 2024, showing the share of revenue converted to profit.
Entera Bio Ltd invested $4.5M in research and development in fiscal year 2024. This represents a decrease of 0.2% from the prior year.
Entera Bio Ltd invested $3K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 82.4% from the prior year.
ENTX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0-100.0% | $42K-48.8% | $82K+43.9% | $57K | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0-100.0% | $42K-48.8% | $82K+70.8% | $48K | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0-100.0% | $9K | $0 | $0 | $0 |
| R&D Expenses | $1.6M+8.1% | $1.5M+35.4% | $1.1M-6.5% | $1.2M+10.6% | $1.1M+47.8% | $735K-26.5% | $1.0M-27.0% | $1.4M |
| SG&A Expenses | $122K+18.4% | $103K-92.8% | $1.4M-59.7% | $3.6M+2565.7% | $134K-89.9% | $1.3M+36.4% | $973K-5.4% | $1.0M |
| Operating Income | -$3.3M-22.0% | -$2.7M-4.1% | -$2.6M-9.7% | -$2.3M-7.9% | -$2.2M-5.0% | -$2.1M-5.0% | -$2.0M+17.7% | -$2.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | $0 | N/A | N/A | $0-100.0% | $29K |
| Net Income | -$3.2M-20.5% | -$2.7M-3.5% | -$2.6M-8.9% | -$2.4M-9.9% | -$2.1M-6.3% | -$2.0M-1.1% | -$2.0M+16.1% | -$2.4M |
| EPS (Diluted) | $0.07+16.7% | $0.060.0% | $0.060.0% | $0.060.0% | $0.06+20.0% | $0.05-28.6% | $0.07-12.5% | $0.08 |
ENTX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $17.4M-11.5% | $19.7M-8.9% | $21.6M+130.0% | $9.4M-6.4% | $10.0M-2.0% | $10.2M-13.0% | $11.8M+37.4% | $8.6M |
| Current Assets | $17.0M-11.9% | $19.3M-9.0% | $21.2M+136.5% | $9.0M-6.5% | $9.6M-1.6% | $9.8M-13.4% | $11.3M+40.4% | $8.0M |
| Cash & Equivalents | $8.6M-21.0% | $10.9M-13.6% | $12.6M+45.2% | $8.7M-4.4% | $9.1M-1.4% | $9.2M-16.6% | $11.0M+45.3% | $7.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0 | $0-100.0% | $126K0.0% | $126K+121.1% | $57K | N/A | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.2M-9.9% | $2.4M+8.6% | $2.2M+69.5% | $1.3M-12.8% | $1.5M+9.2% | $1.4M-0.2% | $1.4M-40.8% | $2.3M |
| Current Liabilities | $1.6M-14.8% | $1.8M+13.6% | $1.6M+38.0% | $1.2M-9.1% | $1.3M+15.4% | $1.1M+2.7% | $1.1M-46.2% | $2.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $15.2M-11.7% | $17.3M-11.0% | $19.4M+139.8% | $8.1M-5.3% | $8.5M-3.7% | $8.9M-14.7% | $10.4M+66.5% | $6.2M |
| Retained Earnings | -$122.3M-2.7% | -$119.2M-2.3% | -$116.5M-2.3% | -$113.9M-5.0% | -$108.5M-2.0% | -$106.4M-1.9% | -$104.4M-1.9% | -$102.4M |
ENTX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.5M-53.4% | -$1.6M-16.2% | -$1.4M+4.3% | -$1.5M-9.9% | -$1.3M+28.3% | -$1.9M+28.8% | -$2.6M-71.6% | -$1.5M |
| Capital Expenditures | $43K+48.3% | $29K+262.5% | $8K+166.7% | $3K | $0 | $0-100.0% | $5K | $0 |
| Free Cash Flow | -$2.5M-53.3% | -$1.7M-17.6% | -$1.4M+3.9% | -$1.5M-10.1% | -$1.3M+28.3% | -$1.9M+29.0% | -$2.6M-71.9% | -$1.5M |
| Investing Cash Flow | -$43K-48.3% | -$29K-262.5% | -$8K-166.7% | -$3K | $0 | $0+100.0% | -$5K | $0 |
| Financing Cash Flow | $250K+590.2% | -$51K-100.4% | $13.3M+314.6% | $3.2M+164.6% | $1.2M+3953.3% | $30K-99.5% | $6.0M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ENTX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 0.0%0.0pp | 0.0%-15.8pp | 15.8% | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -6102.4%-3252.4pp | -2850.0%+948.3pp | -3798.3% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | -6111.9%-3236.3pp | -2875.6%+887.5pp | -3763.2% | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -18.4%-4.9pp | -13.5%-1.6pp | -11.9%+13.2pp | -25.1%-3.7pp | -21.4%-1.7pp | -19.7%-2.7pp | -17.0%+10.8pp | -27.8% |
| Current Ratio | 10.83+0.4 | 10.47-2.6 | 13.07+5.4 | 7.63+0.2 | 7.42-1.3 | 8.70-1.6 | 10.32+6.4 | 3.95 |
| Debt-to-Equity | 0.140.0 | 0.14+0.0 | 0.11-0.0 | 0.16-0.0 | 0.18+0.0 | 0.16+0.0 | 0.13-0.2 | 0.37 |
| FCF Margin | N/A | N/A | -3361.9%-1569.2pp | -1792.7%+549.4pp | -2342.1% | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Entera Bio Ltd's annual revenue?
Entera Bio Ltd (ENTX) reported $181K in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Entera Bio Ltd profitable?
No, Entera Bio Ltd (ENTX) reported a net income of -$9.5M in fiscal year 2024, with a net profit margin of -5271.3%.
What is Entera Bio Ltd's earnings per share (EPS)?
Entera Bio Ltd (ENTX) reported diluted earnings per share of $0.25 for fiscal year 2024. This represents a -19.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Entera Bio Ltd's EBITDA?
Entera Bio Ltd (ENTX) had EBITDA of -$9.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Entera Bio Ltd's gross margin?
Entera Bio Ltd (ENTX) had a gross margin of 5.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Entera Bio Ltd's operating margin?
Entera Bio Ltd (ENTX) had an operating margin of -5295.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Entera Bio Ltd's net profit margin?
Entera Bio Ltd (ENTX) had a net profit margin of -5271.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Entera Bio Ltd's free cash flow?
Entera Bio Ltd (ENTX) generated -$6.8M in free cash flow during fiscal year 2024. This represents a 6.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Entera Bio Ltd's operating cash flow?
Entera Bio Ltd (ENTX) generated -$6.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Entera Bio Ltd's total assets?
Entera Bio Ltd (ENTX) had $9.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Entera Bio Ltd's capital expenditures?
Entera Bio Ltd (ENTX) invested $3K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Entera Bio Ltd spend on research and development?
Entera Bio Ltd (ENTX) invested $4.5M in research and development during fiscal year 2024.
How many shares does Entera Bio Ltd have outstanding?
Entera Bio Ltd (ENTX) had 39M shares outstanding as of fiscal year 2024.
What is Entera Bio Ltd's current ratio?
Entera Bio Ltd (ENTX) had a current ratio of 7.63 as of fiscal year 2024, which is generally considered healthy.
What is Entera Bio Ltd's debt-to-equity ratio?
Entera Bio Ltd (ENTX) had a debt-to-equity ratio of 0.16 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Entera Bio Ltd's return on assets (ROA)?
Entera Bio Ltd (ENTX) had a return on assets of -101.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Entera Bio Ltd's cash runway?
Based on fiscal year 2024 data, Entera Bio Ltd (ENTX) had $8.7M in cash against an annual operating cash burn of $6.8M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Entera Bio Ltd's Piotroski F-Score?
Entera Bio Ltd (ENTX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Entera Bio Ltd's earnings high quality?
Entera Bio Ltd (ENTX) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Entera Bio Ltd?
Entera Bio Ltd (ENTX) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.